Metropolis Healthcare (NSE:METROPOLIS) 3-Year RORE % : 14.69% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:METROPOLIS Metropolis Healthcare Ltd NSE:METROPOLIS
93 GF Score
Price ₹588.45
GF Value ₹602.80
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Metropolis Healthcare 3-Year RORE %?

Metropolis Healthcare NSE:METROPOLIS +2.00% 93 3-Year RORE % is 14.69 as of Jun. 2026. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹602.80 (Fairly Valued). The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 69% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Metropolis Healthcare's 3-Year RORE % for the quarter that ended in Jun. 2026 was 14.69%.

The industry rank for Metropolis Healthcare's 3-Year RORE % or its related term are showing as below:

NSE:METROPOLIS's 3-Year RORE % is ranked better than
69% of 200 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.765 vs NSE:METROPOLIS: 14.69

Metropolis Healthcare  (NSE:METROPOLIS) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Metropolis Healthcare 3-Year RORE % Related Terms


Metropolis Healthcare 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Metropolis Healthcare's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metropolis Healthcare 3-Year RORE % Chart

Metropolis Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.84 -9.81 -22.58 0.52 14.34

Metropolis Healthcare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.59 6.27 11.58 14.34 14.69

NSE:METROPOLIS vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Metropolis Healthcare's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metropolis Healthcare 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Metropolis Healthcare's 3-Year RORE % falls into.


NSE:METROPOLIS
93GF Score
Metropolis Healthcare Ltd NSE:METROPOLIS
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metropolis Healthcare 3-Year RORE % Calculation

Metropolis Healthcare's 3-Year RORE % for the quarter that ended in Jun. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 9.708-6.661 )/( 23.74-3 )
=3.047/20.74
=14.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 14.69 mean?
Metropolis Healthcare (NSE:METROPOLIS) has a 3-Year RORE % of 14.69 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Metropolis Healthcare and its competitors. According to the industry distribution chart, Metropolis Healthcare ranks #62 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 31%.
Is Metropolis Healthcare's 3-Year RORE % too high?
Metropolis Healthcare's current 3-Year RORE % is 14.69. Based on the distribution chart, Metropolis Healthcare ranks #62 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #62 out of 200 companies for 3-Year RORE %. This puts Metropolis Healthcare in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current 3-Year RORE % is 14.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹602.80, compared to a current price of ₹588.45 — trading 2.4% below its estimated fair value. The current 3-Year RORE % is 14.69. Metropolis Healthcare's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current 3-Year RORE % is 14.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued. The current stock price of ₹588.45 is trading 2.4% below its estimated GF Value™ of ₹602.80. GuruFocus considers Metropolis Healthcare to be Fairly Valued.

Key valuation signals for NSE:METROPOLIS:

  • 3-Year RORE %: 14.69
  • GF Value™: ₹602.80 vs. price of ₹588.45 (2.4% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Metropolis Healthcare Business Description

Other Exchanges 542650:India
Address Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score

Get the complete analysis for NSE:METROPOLIS

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹588.45
Price
₹602.80
GF Value